Immunogenicity and Safety of Dengue Tetravalent Vaccine (TDV) and Recombinant 9-valent Human Papillomavirus Vaccine (9vHPV) in Participants Aged ≥9 to < 15 Years

Condition:   Dengue Fever Interventions:   Biological: 9vHPV vaccine;   Biological: Dengue Tetravalent Vaccine (TDV) Sponsor:   Takeda Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials